ArticlePituitary2025
Circadian rhythm proteins as potential biomarkers in pituitary adenomas: an immunohistochemical analysis.
Article in Pituitary, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo investigate the protein expression levels of circadian clock genes in pituitary adenomas (PAs) using the immunohistochemical staining method.
methodsPatients who had regular follow-up at the pituitary center, underwent transsphenoidal surgery (TSS) for PA between 8:00 AM and 2:00 PM, and had sufficient clinical data were enrolled. Patients with a known diagnosis of depression, those receiving psychiatric medication or melatonin agonists that may affect the protein expression of circadian clock genes, or those working night shifts during the preoperative period were excluded. Formalin-fixed paraffin-embedded tissue samples from patients with somatotroph, gonadotroph, lactotroph, and corticotroph adenomas were immunohistochemically stained for BMAL1, CLOCK, CRY1, CRY2, and PER2. Non-neoplastic adenohypophysis tissue adjacent to the adenoma in surgical specimens underwent the same staining procedure and served as the control group. Protein expression levels were then evaluated.
resultsA total of 86 PAs and 17 non-neoplastic adenohypophysis tissue samples were evaluated. Total BMAL1 scores tended to be higher in PAs than in control tissues (170.93 ± 59.81 vs. 142.06 ± 47.40; p = 0.064), whereas total CRY2 scores tended to be lower (12.5 [0-59.25] vs. 35 [10-60]; p = 0.053). Total CLOCK scores were lower in patients with recurrent disease compared to those without recurrence (225 [165-270] vs. 250 [212.5-280]; p = 0.038), and preoperative maximum tumor size was negatively correlated with total CRY2 scores (r=-0.463, p < 0.001). Among PA subtypes, CRY2 was the circadian clock gene showing the most prominent differences.
conclusionAlterations in the protein expression levels of circadian clock genes may contribute to the development and behavior of PAs.
Indexed as
Identifiers
41364136What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.